Britain backs COVID-19 immunity studies with 8.4 million pounds
Reuters
Published Aug 27, 2020 07:13PM ET
LONDON (Reuters) - Britain said on Friday it will back three nationwide COVID-19 studies with 8.4 million pounds ($11 million) to fund research into understanding human immune responses to the pandemic coronavirus.
The funds, from UK Research and Innovation and the National Institute for Health Research, will help scientists develop better immunity tests, study the body's immune response to SARS-CoV-2 and understand why some people suffer life-threatening COVID-19 while others have mild or asymptomatic infections.
"Together, it is hoped these studies will improve the treatment of patients and inform the development of vaccines and therapies," the funding bodies said in a joint statement.
"Importantly, these studies will determine when and how immunity persists or whether people can become re-infected (with COVID-19)."
The funding will be split between the UK Coronavirus Immunology Consortium, which will get 6.5 million pounds to study how effective immunity is developed and why people respond differently to the disease, and another research collaboration which will get 1.5 million to study the humoral immune response - molecules produced by the immune system to fight infection.
Just under 400,000 pounds will fund a third project looking at key features of fatal COVID-19 and the impact the virus has upon the lungs and other vital organs.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.